Research programme: PRS 300 Series - Pieris Pharmaceuticals

Drug Profile

Research programme: PRS 300 Series - Pieris Pharmaceuticals

Alternative Names: Anticalin®-antibody fusion proteins - Pieris Pharmaceuticals; PRS-300 Series A; PRS-300 Series B & C; PRS-300 Series D; PRS-332

Latest Information Update: 13 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pieris
  • Developer Pieris Pharmaceuticals
  • Class Antibodies; Lipocalins
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 05 Jan 2017 PRS 332 program licensed to Servier worldwide excluding USA for the treatment of Cancer
  • 18 Dec 2014 Preclinical trials in Cancer in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top